{"title":"树突状细胞II:抗肿瘤疫苗的临床应用","authors":"Manuel Sureda, M. Begoña Vázquez, Joseba Rebollo","doi":"10.1016/j.inmuno.2011.10.002","DOIUrl":null,"url":null,"abstract":"<div><p>Cancer immunotherapy seeks to mobilize the patient's immune system for therapeutic benefit. It can be active, as in vaccination. Dendritic cells play a central role in immune response. The type of immune response obtained depends on the regulation by the DC. Ex vivo generated and antigen-loaded DC have been used as vaccines to improve immunity in patients with cancer and chronic HIV infection, thus providing a “proof-of-principle” that DC vaccines can work. Nine preparations for antitumoral vaccination in patients have achieved phase III studies. Between them, only sipuleucel-T, for the treatment of metastatic hormone refractory prostate cancer, using DC, has received a preliminary approval of the FDA of the United States.</p></div>","PeriodicalId":88896,"journal":{"name":"Inmunologia (Barcelona, Spain : 1987)","volume":"31 2","pages":"Pages 43-48"},"PeriodicalIF":0.0000,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.inmuno.2011.10.002","citationCount":"1","resultStr":"{\"title\":\"Células dendríticas II: utilización clínica en vacunación antitumoral\",\"authors\":\"Manuel Sureda, M. Begoña Vázquez, Joseba Rebollo\",\"doi\":\"10.1016/j.inmuno.2011.10.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Cancer immunotherapy seeks to mobilize the patient's immune system for therapeutic benefit. It can be active, as in vaccination. Dendritic cells play a central role in immune response. The type of immune response obtained depends on the regulation by the DC. Ex vivo generated and antigen-loaded DC have been used as vaccines to improve immunity in patients with cancer and chronic HIV infection, thus providing a “proof-of-principle” that DC vaccines can work. Nine preparations for antitumoral vaccination in patients have achieved phase III studies. Between them, only sipuleucel-T, for the treatment of metastatic hormone refractory prostate cancer, using DC, has received a preliminary approval of the FDA of the United States.</p></div>\",\"PeriodicalId\":88896,\"journal\":{\"name\":\"Inmunologia (Barcelona, Spain : 1987)\",\"volume\":\"31 2\",\"pages\":\"Pages 43-48\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.inmuno.2011.10.002\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inmunologia (Barcelona, Spain : 1987)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0213962611000692\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inmunologia (Barcelona, Spain : 1987)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213962611000692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Células dendríticas II: utilización clínica en vacunación antitumoral
Cancer immunotherapy seeks to mobilize the patient's immune system for therapeutic benefit. It can be active, as in vaccination. Dendritic cells play a central role in immune response. The type of immune response obtained depends on the regulation by the DC. Ex vivo generated and antigen-loaded DC have been used as vaccines to improve immunity in patients with cancer and chronic HIV infection, thus providing a “proof-of-principle” that DC vaccines can work. Nine preparations for antitumoral vaccination in patients have achieved phase III studies. Between them, only sipuleucel-T, for the treatment of metastatic hormone refractory prostate cancer, using DC, has received a preliminary approval of the FDA of the United States.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
